HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Hematopoietic cells raising with plerixafor in non-Hodgkin lymphoma].

AbstractBACKGROUND:
bone marrow autologous transplantation (BMAT) has proven benefits in patients treated for non-Hodgkin's lymphoma (NHL). Plerixafor is an inhibitor of CXCR4 receptor. The aim was to report the raise of hematopoietic cells with plerixafor in patients with NHL.
CLINICAL CASES:
patient 1 with follicular NHL, GI, intermediate FLIPI, CD20+, CD45+, BCL-2+, who reached complete response after three chemotherapy regimes. Mobilization failed after use of filgrastim (G-CSF) alone and G-CSF + cyclophosphamide. A new attempt was made with G-CSF + plerixafor (G-CSF, 10 μg/kg for 7 days + plerixafor, 240 μg/kg in days 4 to 7). Patient 2 with follicular NHL and CD20+ reached complete remission with MINE after therapeutic failure with other regimes, but develops severe marrow toxicity. Mobilization was supported with G-CSF 10 μg/kg/d + plerixafor in days 4 and 5. In case one, proper cell counts where obtained after three aphaeresis. In the second case, two harvests add of 2.7 × 106/kg were obtained.
CONCLUSIONS:
plerixafor raised the hematopoietic stem cells in peripheral blood and improves mobilization of proper cell population.
AuthorsUendy Pérez-Lozano, Francisco Tripp-Villanueva, Aline Ramírez-Alvarado, Jorge Vela-Ojeda, Alejandro Limón-Flores, José Luis Kramis-Cerezo
JournalRevista medica del Instituto Mexicano del Seguro Social (Rev Med Inst Mex Seguro Soc) 2012 Jul-Aug Vol. 50 Issue 4 Pg. 449-51 ISSN: 0443-5117 [Print] Mexico
Vernacular TitleMovilización de células hematopoyéticas con plerixafor en linfoma no Hodgkin folicular.
PMID23234751 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Benzylamines
  • Cyclams
  • Heterocyclic Compounds
  • plerixafor
Topics
  • Adult
  • Benzylamines
  • Cyclams
  • Hematopoietic Stem Cell Mobilization (methods)
  • Heterocyclic Compounds (therapeutic use)
  • Humans
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: